|ATC code||G03FA16 (WHO)|
|Chemical and physical data|
|Molar mass||342.472 g/mol|
|3D model (Jmol)||Interactive image|
Trimegestone (INN) (brand name Ondeva), also known as 21-hydroxypromegestone, as well as 17β-((S)-2-hydroxypropanoyl)-17α-methylestra-4,9-dien-3-one, is a steroidal progestin of the 19-norprogesterone group related to promegestone which was introduced in France in 2001 and is used as a hormonal contraceptive and in hormonal replacement therapy for postmenopausal symptoms. It is not available in the United States.
Trimegestone has very high affinity for the progesterone receptor, only weak affinity for the mineralocorticoid receptor, and little or no affinity for other steroid hormone receptors. In accordance, it is described as a very potent and pure progestogen, in fact the most potent progestin of the 19-norprogesterone group (clinically effective in endometriosis at only 0.1 mg/day), and possesses weak antimineralocorticoid activity and no androgenic, antiandrogenic, estrogenic, or glucocorticoid activity. Due to its unique structure, unlike progesterone and some other progestins, trimegestone does not metabolize into neuroactive steroids, and hence does not influence GABAA receptor signaling.
- C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 2063–. ISBN 978-0-412-46630-4.
- Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 208–. ISBN 978-3-527-62330-3.
- Winnifred Cutler (30 March 2009). Hormones and Your Health: The Smart Woman's Guide to Hormonal and Alternative Therapies for Menopause. John Wiley & Sons. pp. 43–. ISBN 978-0-470-52553-1.
- Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 273, 647. ISBN 978-0-12-397214-9.
- Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1403–. ISBN 978-1-60913-345-0.
- Kuhl, H (2009). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137.
- Winneker RC, Bitran D, Zhang Z (2003). "The preclinical biology of a new potent and selective progestin: trimegestone". Steroids. 68 (10-13): 915–20. PMID 14667983.